Sarcoid-like reaction in cases treated by checkpoint inhibitors.
Checkpoint inhibitor
Clinical outcome
Sarcoid-like reaction
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
18 Feb 2021
18 Feb 2021
Historique:
received:
04
01
2021
accepted:
29
01
2021
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Sarcoidosis is a multisystem granulomatous disorder characterized by helper T cell inflammation. Sarcoid-like reaction (SLR) is a well-defined entity and may be related with several malignant disorders and/or their therapies. SLR has been reported more than 20 years ago and in recent years in cases treated by checkpoint inhibitors (CPIs). Better outcome has been reported in cases developing granulomatous reaction and/or SLRs during CPI treatments. However, these lesions clinically may be thought as disease progression and may cause to stop treatment or alterations. These therapeutic manipulations may be harmful for the patients. Clinicians should be aware of SLRs in cases treated by CPIs and tissues must be sampled and reviewed by an experienced pathologist to avoid misdiagnosis and also unnecessary CPI treatment cessations.Significance StatementClinicians should be aware of sarcoid-like reactions in cases treated by checkpoint inhibitors and tissues must be sampled and reviewed by an experienced pathologist to avoid misdiagnosis and CPI treatment stops.
Identifiants
pubmed: 33598792
doi: 10.1007/s12032-021-01477-y
pii: 10.1007/s12032-021-01477-y
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Références
Hunt BM, Valliers E, Buduhan G, Aye R, Louie B. Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg. 2009;197:629–32.
pubmed: 19321155
Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007;25:326–33.
pubmed: 17560310
Paydas S, Yavuz S, Disel U, Zeren H, Hastürk S, Hanta I, Ergin M, Sahin B. Granulomatous reaction after chemotherapy for Hodgkin’s disease. Leuk Res. 2002;26:967–70.
pubmed: 12163060
Suditu N, Negru D. Bacillus Calmette–Guerin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: a case report and literature review. Mol Clin Oncol. 2015;3:249–51.
pubmed: 25469304
Clerigo V, Castro A, Mourato T, Gomes C. A rare case of granulomatous pneumonitis due to intravesical BCG for bladder cancer. Acta Med Port. 2019;32:316–20.
pubmed: 31067427
Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218:69–70.
pubmed: 18832811
Danlos FX, Pages C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, Jebali M, Bagot M, Tazi A, Lebbe C. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149:133–6.
Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS Nishino M. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3:1185–92.
pubmed: 26100356
pmcid: 4596761
Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, Ave E, Gattazzo C, Fadini GP, Calabrese F, Semenzato G, Agostini C. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66:144–50.
pubmed: 21139119
Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, Hendriks RW, Kleinjan A. Increased IL17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology. 2012;51:37–46.
pubmed: 22075064
Naccache JM, Antoine M, Wislez M, Fleury-Feith J, Oksenhendler E, Mayaud C, Cadranel J. Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Am J Respir Crit Care Med. 1999;159:2009–13.
pubmed: 10351953
Ishida M, Hodohara K, Furuya A, Okuno H, Yoshii M, Horinouchi A, Yoshida T. Sarcoidal granulomas in the mediastinal lymph nodes after treatment for marginal zone lymphoma of the esophagus: report of a case with review of the concept of the sarcoidosis-lymphoma syndrome. Int J Clin Exp Pathol. 2014;7(7):4428–32.
pubmed: 25120829
pmcid: 4129064
Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639–46.
pubmed: 17486092
Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, Abreu MT, Unutmaz D, Sundrud MS. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014;211:89–104.
pubmed: 24395888
pmcid: 3892977
Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, Woodruff PG, Bhakta NR, Christian L, Nguyen CP, Antalek BJ, Benn BS, Hendriks RW, van den Blink B, Kool M, Koth LL. IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193:1281–91.
pubmed: 26649486
pmcid: 4910899
Lomax AJ, Mcguire HM, Mcneil C, Choi CJ, Hersey P, Karikios D, Shannon K, Van Hal S, Carr U, Crotty A, Gupta SK, Hollingsworth J, Kim H, Groth BF, Mcgill N. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017;20:1277–85.
pubmed: 28480561
Braun NA, Celada LJ, Herazo-Maya JD, Abraham S, Shaginurova G, Sevin CM, Grutters J, Culver DA, Dworski R, Sheller J, Massion PP, Polosukhin VV, Johnson JE, Kaminski N, Wilkes DS, Oswald-Richter KA, Drake WP. Blockade of the programmed death-1 pathway restores sarcoidosis CD4
Zou W, Wolchok JD, Chen L. PD-L1 (B7eH1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations. Sci Transl Med. 2016;8:328.
Saidha S, Sotirchos ES, Eckstein C. Etiology of sarcoidosis: does infection play a role? Yale J Biol Med. 2012;85:133–41.
pubmed: 22461752
pmcid: 3313528
Al-dliw M, Megri M, Shahoub I, Sahay G, Limjoco TI, Shweihat Y. Pembrolizumab reactivates pulmonary granulomatosis. Respir Med Case Rep. 2017;22:126–9.
pubmed: 28794963
pmcid: 5540828
Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Pembrolizumab associated sarcoidosis. JAAD Case Rep. 2016;2:290–3.
pubmed: 27504482
pmcid: 4969257
Burillo-Martinez S, MoralesRaya C, Prieto-Barrios M, Rodriguez-Peralto JL, Ortiz-Romero P-L. Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum. JAMA Dermatol. 2017;153:721–2.
pubmed: 28467548
Lopez AT, Khana T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57:664–9.
pubmed: 29630716
Wu J, Kwong BY, Martires KJ, Rieger KE, Chung WH, Iyer GV, Lacouture ME. Granuloma annulare associated with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol. 2018;32:124–6.
Hiraki T, Hatanaka M, Arimura A, Kawahira H, Kirishimal M, Kitazono I, Horinouchi M, Higashi M, Kanekura T, Tanimoto A. Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence. J Cutan Pathol. 2020;47:154–60.
pubmed: 31437317
Mitchell MA, Hogan K, Amjadi K. Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. Immunotherapy. 2018;10:1189–92.
pubmed: 30326785
Lafon M, Blaye C, Kind M, Bechade D, Chassaigne F, Italiano A, Grellety T. Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1. Breast J. 2019;25:971–3.
pubmed: 31165561
Balestra R, Benzaquen S, Wang J. Sarcoidosis-like granulomatous lung reaction associated with anti-programmed death receptor-1 ligand therapy. Ann Am Thorac Soc. 2017;14:296–9.
pubmed: 28146383
Garcıa-Manso IG, del Mar Garda Rodenas M, Barroso Medel ME, Illân Gambın FJ. Sarcoidosis-like granulomatous reaction associated with pembrolizumab immunotherapy. Sci Lett/Arch Bronconeumol. 2018;54:592–3.
Cervantes J, Rosen A, Dehesa L, Dickinson G, Alonso-Llamazares J. Granulomatous reaction in a patient with metastatic melanoma treated with ipilimumab: first case reported with isolated cutaneous findings. Actas Dermosifiliogr. 2019;110(1):43–9.
pubmed: 30389125
Honigman AD, Lai F, Elakis J, Prall O, Goh M, McCormack C. Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient. Clin Case Rep. 2019;7:773–5.
pubmed: 30997084
pmcid: 6452463
Cousin S, Toulmonde M, Kind M, Cazeau AL, Bechade D, Coindre JM, Italiano A. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol. 2016;27:1178–9.
pubmed: 27091806
Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017;23:620–4.
pubmed: 27590328
Reuss JE, Kunk PR, Stowman AM, Gru AA, Slingluff CL, Gaughan EM. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report and review of the literature. J Immunother Cancer. 2016;4:94.
pubmed: 28031822
pmcid: 5168862
Wigenhof S, Mortion V, Seghers AC. Du four S, Wanderlinden E, Hanon S, Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitör. Anticancer Res. 2012;32:1355–9.
Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant. 2017;32:936–42.
pubmed: 28025384
Andersen R, Norgaard P, Al-Jailawi MK, Svane IM. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology. 2014;3:954506.
van Baar MLM, Guminski AD, Ferguson PM, Martin LK. Pembrolizumab for cutaneous squamous cell carcinoma: report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. JAAD Case Rep. 2019;5:491–4.
pubmed: 31193588
pmcid: 6536769
Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. J Immunother Cancer. 2016;4:1–8.
Cornejo CM, Haun P, English J, Rosenbach M. Immune checkpoint inhibitors and the development of granulomatous reactions. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.07.051 .
doi: 10.1016/j.jaad.2018.07.051
pubmed: 30092327
Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol. 2018;45:504–7.
pubmed: 29633300
Berthol G, Lazor R, Letonovic I, Romano E, Noirez L, Stalder JM, Speiser DE, Peters S, Michielin O. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30:156–9.
Montaudie H, Pradelli J, Passeron T, Lacour JP, Leroy S. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol. 2017;176:1060–3.
pubmed: 27291635
Murphy KP, Kennedy MP, Barry JE, O’Regan KN, Power DG. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat. 2014;37:351–3.
pubmed: 24903767
Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018;6(1):14.
pubmed: 29433571
pmcid: 5810034
Zhang Y, Liu Z, Tian M, Hu X, Wang L, Ji J, Liao A. The altered PD-1/PD-L1 pathway delivers the ‘one-two punch’ effects to promote the Treg/Th17 imbalance in pre-eclampsia. Cell Mol Immunol. 2018;15:710–23.
pubmed: 28890543
Woodbeck R, Metelitsa AI, Naert KA. Granulomatous tumoral melanosis associated with pembrolizumab therapy: a mimicker of disease progression in metastatic melanoma. Am J Dermatopathol. 2018;40:523–6.
pubmed: 29924748
O’Kane GM, Labre C, Doherty MK, Young K, Albalâ H, Leigbl NB. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist. 2017;22:70–80.
pubmed: 27534573
Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230–40.
pubmed: 27401894
pmcid: 5061539
Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, Joo HO, Gabrielson EW, Shankar LK, Wahl RL. A comparison of FLT to FDGPET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC. EJNMMI Res. 2017;7:8.
pubmed: 28102506
pmcid: 5247390
Yeh R, Trager MH, Rizk ME, Finkel GG, Barker LW, Carvajal RD, Geskin LJ, Schwartz GK. FLT-PET at 6 weeks predicts response assessed by CT at 12 weeks in melanoma patients treated with pembrolizumab. Clin Nucl Med. 2020;45:267–77.
pubmed: 32108700
Li Z, Graf N, Herrmann K, Jünger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. Cancer Res. 2012;72:5014–24.
pubmed: 22875026